Strong Revenue Growth
Revenue for Q3 2025 was $36.2 million, up $7.5 million or 26% compared to 2024. Screening revenue increased by 29% and U.S. Gallery revenue was up 28% year-over-year.
Significant Clinical Trial Results
The PATHFINDER II study showed a more than sevenfold increase in overall cancer detection rate, with Gallery's positive predictive value (PPV) at 61.6% and specificity at 99.6%.
Successful Financial Strategy
Completed a $325 million private placement, strengthening the balance sheet. Cash and investments are approximately $850 million, extending the cash runway into 2030.
International Expansion
Announced a strategic collaboration with Samsung to commercialize Gallery in South Korea and potentially other Asian markets.
Operational Efficiency
Non-GAAP adjusted gross profit increased by 60% compared to 2024, with a gross margin of 55% due to improvements in lab efficiency and cost management.
Encouraging SIMPLIFY Study Outcomes
Updated PPV in symptomatic populations increased to 84.2%, with long-term follow-up showing many initially false positives were later diagnosed with cancer.